.Attribute Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after an unfavorable trial, which highlights the many intricacies and challenges of medicine advancement within this setting.